

Atty. Docket No. 38355-1030

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:) Confirmation No.: 7970
Darryl Rideout et al.)
Serial No.: 10/550,372) Group Art Unit: 1628
Filed: September 18, 2006) Examiner: Kathrien Ann Cruz
For: INHIBITORS OF ANTHRAX)
LETHAL FACTOR)


San Diego, California
September 30, 2011Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450**DECLARATION OF DR. KAL RAMNARAYAN UNDER 37 C.F.R. § 1.132**

I, Dr. Kal Ramanarayan, Ph.D., declare:


1. I am the Co-founder, President and Chief Scientific Officer of Sapient Discovery, a company that leverages its molecular structure design expertise, proprietary structural databases, and proprietary computational methodologies to help its clients accelerate the drug discovery and drug design processes. Previously, I was Co-founder, Vice President and Chief Scientific Officer of Structural Bioinformatics Inc. ("SBI"), which subsequently changed its name to Cengent Therapeutics Inc. ("Cengent").
2. While at SBI and Cengent, I led a team in National Institute of Health ("NIH") Project No. 2R44AI045237-02A1, a Small Business Research grant-funded project relating to discovery and identification of compounds that act as inhibitors of Anthrax Lethal Factor activity. This research lasted several years and yielded a number of compounds that

inhibit matrix metalloproteases, a family of enzymes of which Anthrax Lethal Factor is a member.

3. The work from that study lead to two patent applications, one for some of the earlier compounds discovered during our screening and structure-relationship studies, and one for some of the compounds discovered later in the process. The first was U.S. Application Serial No. 09/818,259, later granted as U.S. Patent No. 6,436,933, initially owned by SBI, which discloses and claims certain compounds for treating anthrax infections by inhibiting Anthrax Lethal Factor activity, the compounds having the general formula:




4. The second patent application is the present application, U.S. Application Serial No. 10/550,372, initially owned by Cengent Therapeutics, disclosing and claiming later-discovered compounds for treating anthrax infections by inhibiting Anthrax Lethal Factor activity, the compounds having the general formula:




5. In conclusion, the invention disclosed and claimed in U.S. Patent No. 6,436,933 is my own previous work. I worked for SBI (later Cengent), the owner of the patent, at the time the work was done. The invention of the present application grew out of the same work and discloses and claims compounds discovered later as part of the same study.

I declare under penalty of perjury under the laws of the United States that the foregoing is true and correct.


(Signature)

Kal Ramnarayan
(Type Name)


9/30/11
(Date)